Status:
COMPLETED
Vildagliptin in Older Adults With Diabetes and Mild Cognitive Impairment
Lead Sponsor:
University of Catania
Conditions:
Mild Cognitive Impairment
Eligibility:
All Genders
65+ years
Phase:
PHASE4
Brief Summary
This study investigates the effect of vildagliptin, an inhibitor of the enzyme DPP-4, on the cognitive functioning of elderly diabetic patients with mild cognitive impairment (MCI) documented at mini ...
Eligibility Criteria
Inclusion
- age \>65 years
- MMSE score ≥18 and ≤23
- diagnosis of diabetes mellitus
Exclusion
- heart failure
- coronary heart disease
- stroke
- chronic kidney disease (G3 grade KDOQI)
- liver cirrhosis
- chronic respiratory failure
- depression evaluated by Geriatric Depression (GDS, GDS \>15)
- diagnosis of dementia based on DSM 5 criteria
- anticholinesterase or memantine therapy
Key Trial Info
Start Date :
January 1 2015
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2016
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT03819127
Start Date
January 1 2015
End Date
September 1 2016
Last Update
January 28 2019
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.